Scientific Programme
The 21st Annual ENETS Conference
13 - 15 March 2024
14th Annual ENETS Postgraduate Course
Wednesday, 13 March 2024
REGISTRATION & COFFEE
Welcome and opening – 21st Annual ENETS Conference
Opening & overview – 14th Annual ENETS Postgraduate Course
Session A: Follow-up after R0 resection of thoracic and digestive NET
09:00 - 09:15 | Recurrence free survival of thoracic and digestive NET: What we know about type and frequency
|
Eric Baudin, FRA |
09:15 - 09:20 | Q & A
|
09:20 - 09:35 | Performance of PET imaging to detect recurrence: State of the art
|
Valentina Ambrosini, ITA |
09:35 - 09:40 | Q & A
|
09:40 - 09:55 | Functioning syndrome: Is it a good marker of recurrence?
|
Hans Hofland, NED |
09:55 - 10:00 | Q & A
|
10:00 - 10:30 | Panel discussion
|
COFFEE BREAK
Session B: Imaging session for NET – A guide for clinicians
11:00 - 11:15 | Feature of primary, node and liver mets of digestive NET at CT or MRI at diagnosis and treatment alteration
|
Anders Sundin, SWE |
11:15 - 11:20 | Q & A
|
11:20 - 11:35 | Features of bone mets at CT or MRI at diagnosis and treatment alteration
|
Timm Denecke, GER |
11:35 - 11:40 | Q & A
|
11:40 - 11:50 | Pathological aspects
|
Tu Vinh Luong, GBR |
11:50 - 11:55 | Q & A
|
How do I select unresectable NET patients for PRRT: The good, the bad, the unknown (11:55 - 12:10) |
Moderators: |
11:55 - 12:00 | Oncologist's view
|
Margot Tesselaar, NED |
12:00 - 12:05 | Endocrinologist's view
|
Emanuel Christ, SUI |
12:05 - 12:10 | Gastroenterologist's view
|
Ivan Borbath, BEL |
12:10 - 12:30 | Panel discussion
|
Ivan Borbath, BEL / Emanuel Christ, SUI / Timm Denecke, GER / Christophe Deroose, BEL / Tu Vinh Luong, GBR / Anders Sundin, SWE / Margot Tesselaar, NED |
LUNCH BREAK
Poster presentation – Clinical science
13:00 - 13:04 | Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) – DUTHY (GETNE-T1812) trial
|
Alejandro Garcia-Alvarez, ESP |
13:04 - 13:07 | Discussion
|
13:07 - 13:11 | Identification of new biomarkers associated with prognosis of pancreatic neuroendocrine neoplasms and establishment of survival prediction model
|
Qiyun Tang, CHN |
13:11 - 13:14 | Discussion
|
13:15 - 13:19 | Identifying patients with undiagnosed small intestinal neuroendocrine tumors using statistical and machine learning: Model development and validation study
|
Mohid Khan, GBR |
13:19 - 13:22 | Discussion
|
13:22 - 13:26 | Familial midgut neuroendocrine tumors (FM-NETs): Results of the nationwide TCF cohort from the GTE-RENATEN network
|
Louis de Mestier, FRA |
13:26 - 13:29 | Discussion
|
13:30 - 13:34 | Interim safety and exploratory efficacy results of a phase 2, randomized, parallel-group study of oral Paltusotine treatment in subjects with carcinoid syndrome
|
Simron Singh, CAN |
13:34 - 13:37 | Discussion
|
13:38 - 13:42 | TECANT ERA PerMed study – Somatostatin receptor antagonists as a new sensitive diagnostic tool for reliable assessment of the SSTR status in neuroendocrine neoplasms
|
Marta Opalinska, POL |
13:42 - 13:45 | Discussion
|
Poster presentation – Basic and translational science
13:00 - 13:04 | Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterization and monitoring
|
Carlota Arenillas Lallana, ESP |
13:04 - 13:07 | Discussion
|
13:07 - 13:11 | Machine-learning identified optimized classification models for the diagnosis of typical and atypical lung carcinoids based on the genomic variance
|
Yi-Ying Guo, CHN |
13:11 - 13:14 | Discussion
|
13:15 - 13:19 | Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets
|
Olivia Debnath, GER |
13:19 - 13:22 | Discussion
|
13:22 - 13:26 | Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumors in the lungNENomics project
|
Émilie Mathian, FRA |
13:26 - 13:29 | Discussion
|
13:30 - 13:34 | Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition
|
Yotam Drier, ISR |
13:34 - 13:37 | Discussion
|
13:38 - 13:42 | Cell-free DNA (cfDNA) methylation profiling for minimally invasive cancer detection in patients with Extra-Pulmonary NeuroEndocrine Carcinoma (EP-NEC)
|
Melissa Frizziero, GBR |
13:42 - 13:45 | Discussion
|
Session C: Does epidemiology affect the care of NEN patients?
14:00 - 14:15 | Are NET over diagnosed? Which consequence on clinical practice?
|
Francesco Panzuto, ITA |
14:15 - 14:30 | Environmental factors – How do these influence preventional care?
|
Raj Srirajaskanthan, GBR |
Management of incidentalomas across thoracic and digestive NET primaries – Are we consistent? (14:30 - 15:00) |
Moderators: |
14:30 - 14:45 | Gastroenterologist's view
|
Anja Rinke, GER |
14:45 - 15:00 | Surgeon's view
|
Els Nieveen van Dijkum, NED |
15:00 - 15:30 | Panel discussion
|
COFFEE BREAK
Session D: MDT – Select the best locoregional therapy in slowly progressive NETs
16:00 - 16:25 | Case 1: Liver mets
|
Jaume Capdevila, ESP |
MDT panel discussion
Jaume Capdevila, ESP / Chris Chandler, GBR / Louis de Mestier, FRA / Frédéric Deschamps, FRA / Beata Kos-Kudła, POL / Stefano Partelli, ITA / Anders Sundin, SWE / Dario Zerini, ITA
16:25 - 16:50 | Case 2: Bone mets
|
Mairead McNamara, GBR |
MDT panel discussion
Jaume Capdevila, ESP / Chris Chandler, GBR / Louis de Mestier, FRA / Frédéric Deschamps, FRA / Beata Kos-Kudła, POL / Stefano Partelli, ITA / Anders Sundin, SWE / Dario Zerini, ITA
16:50 - 17:15 | Case 3: Ablation of small incidental pancreatic primary
|
Louis de Mestier, FRA |
MDT panel discussion
Jaume Capdevila, ESP / Chris Chandler, GBR / Louis de Mestier, FRA / Frédéric Deschamps, FRA / Beata Kos-Kudła, POL / Stefano Partelli, ITA / Anders Sundin, SWE / Dario Zerini, ITA
Summary from locoregional panel (17:15 - 17:35) |
Moderators: |
17:15 - 17:25 | Surgeon's view
|
Chris Chandler, GBR / Stefano Partelli, ITA |
17:25 - 17:30 | Interventional radiologist's view
|
Frédéric Deschamps, FRA |
17:30 - 17:35 | Radiotherapist's view
|
Dario Zerini, ITA |
Closing comments – 14th Annual ENETS Postgraduate Course
ENETS projects
17:40 - 17:50 | European Board in Neuroendocrine Neoplasia Medicine (EBNEN)
|
Andreas Pascher, GER |
17:50 - 18:00 | ENETS projects
|
Eva Tiensuu Janson, SWE |
2nd ENETS Basic and Translational NET Research – A Forum on Basic and Translational Science in Neuroendocrine Neoplasms
Wednesday, 13 March 2024
REGISTRATION & COFFEE
Welcome and opening – 21st Annual ENETS Conference (livestream from Hall E)
Welcome – 2nd ENETS basic and translational NET research forum
Session 1: Cells of origin in NENs
09:00 - 09:15 | Cells of origin in PanNENs
|
Aurel Perren, SUI |
09:15 - 09:20 | Discussion
|
09:20 - 09:35 | Cells of origin in gastric NENs
|
Roland Rad, GER |
09:35 - 09:40 | Discussion
|
09:40 - 09:55 | Cells of origin in lung NENs
|
Michele Simbolo, ITA |
09:55 - 10:00 | Discussion
|
10:00 - 10:07 | Oral Abstract Presentation: Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors
|
Amy Webster, GBR |
10:07 - 10:10 | Discussion
|
10:10 - 10:17 | Oral Abstract Presentation: The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation
|
Samuel Backman, SWE |
10:17 - 10:20 | Discussion
|
10:20 - 10:30 | Session summary
|
COFFEE BREAK
Session 2: Immune tumor microenvironment and opportunities for therapy in NENs
11:00 - 11:15 | The road from nSARS-CoV-2 vaccines to therapeutic vaccines against cancer: Where are we?
|
Luigi Buonaguro, ITA |
11:15 - 11:20 | Discussion
|
11:20 - 11:35 | Adoptive cellular therapies and innovative immunotherapeutic approaches against NENs
|
Anna Mondino, ITA |
11:35 - 11:40 | Discussion
|
11:40 - 11:55 | The roles of extracellular vesicles in the immune system
|
Edit Buzás, HUN |
11:55 - 12:00 | Discussion
|
12:00 - 12:07 | Oral Abstract Presentation: Ex vivo expansion of TILs from panNET liver metastasis: In search of novel adoptive transfer strategies for the treatment of NETs
|
Nada Chaoul, ITA |
12:07 - 12:10 | Discussion
|
Emerging issues on NET basic research (12:10 - 12:30) |
Moderators: |
12:10 - 12:17 | Oral Abstract Presentation: Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy
|
Martin Sadowski, SUI |
12:17 - 12:20 | Discussion
|
12:20 - 12:27 | Oral Abstract Presentation: Establishment of novel patient-derived preclinical models for neuroendocrine tumors
|
Iacovos Michael, CAN |
12:27 - 12:30 | Discussion
|
LUNCH BREAK
Session 3: DAXX/ATRX and MEN1 role in NET tumorigenesis
14:00 - 14:10 | DAXX/ATRX and MEN1 function in healthy tissues
|
Kate Lines, GBR |
14:10 - 14:15 | Discussion
|
14:15 - 14:30 | Oncogenic mechanisms associated with DAXX/ATRX and MEN1 alterations in NETs and what we still do not understand
|
Ilaria Marinoni, SUI |
14:30 - 14:35 | Discussion
|
14:35 - 14:50 | Clinical impact of DAXX/ATRX alterations in NETs: A two-faced role
|
Jérôme Cros, FRA |
14:50 - 14:55 | Discussion
|
14:55 - 15:02 | Oral Abstract Presentation: Transcriptomic analysis of PanNET tumor progression from microtumor to metastasis in MEN1 patients
|
Aziz Chouchane, SUI |
15:02 - 15:05 | Discussion
|
15:05 - 15:12 | Oral Abstract Presentation: MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs
|
Juan Luis Catoya, ESP |
15:12 - 15:15 | Discussion
|
15:15 - 15:22 | Oral Abstract Presentation: New insights into the progression of NET G3 with a focus of NETs with NEC-like transformation
|
Atsuko Kasajima, GER |
15:22 - 15:25 | Discussion
|
15:25 - 15:30 | Session summary
|
COFFEE BREAK
Session 4: Biology of PRRT
16:00 - 16:15 | PRRT mechanisms of action: Known and unknown
|
Julie Nonnekens, NED |
16:15 - 16:20 | Discussion
|
16:20 - 16:35 | How can we advance PRRT, new preclinical model?
|
Alexandre Lugat, FRA |
16:35 - 16:40 | Discussion
|
16:40 - 16:55 | Red marrow toxicities of PRRT: Biological mechanisms
|
Susanne Kossatz, GER |
16:55 - 17:00 | Discussion
|
17:00 - 17:07 | Oral Abstract Presentation: 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE
|
Jon Sponheim, NOR |
17:07 - 17:10 | Discussion
|
17:10 - 17:17 | Oral Abstract Presentation: Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors
|
Sandrine Oziel-Taieb, FRA |
17:17 - 17:20 | Discussion
|
17:20 - 17:30 | Conclusive remarks
|
Mauro Cives, ITA / Anne Couvelard, FRA / Jérôme Cros, FRA / Ilaria Marinoni, SUI |
Closing comments – 2nd ENETS basic and translational NET research forum
21st Annual ENETS Conference
Wednesday, 13 March 2024
Welcome reception
Thursday, 14 March 2024
Satellite Symposium – Industry-sponsored
Session 1: Interdisciplinary management of neuroendocrine tumor syndromes – Which tools for which goals?
09:00 - 09:20 | Keynote speech: MEN-1 – State of the art
|
Rajesh Thakker, GBR |
09:20 - 09:30 | Molecular approaches for the diagnosis of hereditary NEN in 2023 – The geneticist view
|
Attila Patócs, HUN |
09:30 - 09:40 | MEN-2-3-4
|
Gerlof Valk, NED |
09:40 - 09:45 | Discussion
|
09:45 - 09:55 | von Hippel Lindau disease
|
Gregory Kaltsas, GRE |
09:55 - 10:00 | Discussion
|
10:00 - 10:10 | Inherited small intestinal NET
|
Eva Tiensuu Janson, SWE |
10:10 - 10:15 | Discussion
|
10:15 - 10:22 | Oral Abstract Presentation: Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia
|
Jerena Manoharan, GER |
10:22 - 10:25 | Discussion
|
10:25 - 10:30 | Final comments & Wrap-up
|
Anne Couvelard, FRA / Antongiulio Faggiano, ITA |
COFFEE BREAK
Session 2A: Drug development in NENs – Where are we heading?
11:00 - 11:10 | Development of SST-targeted drugs: Current and future perspectives
|
Simona Glasberg, ISR |
11:10 - 11:15 | Discussion
|
11:15 - 11:25 | Update on clinical trials with systemic therapies in NETs
|
Francesca Spada, ITA |
11:25 - 11:30 | Discussion
|
11:30 - 11:40 | Update on clinical trials with systemic therapies in NECs
|
Thomas Walter, FRA |
11:40 - 11:45 | Discussion
|
11:45 - 11:55 | What can we achieve with molecular profiling of NENs and when should it be done?
|
Marianne Pavel, GER |
11:55 - 12:00 | Discussion
|
12:00 - 12:10 | T-Cell redirecting strategies in NENs: CARs, BiTEs and beyond
|
Mauro Cives, ITA |
12:10 - 12:15 | Discussion
|
12:15 - 12:22 | Oral Abstract Presentation: Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)
|
Jaume Capdevila, ESP |
12:22 - 12:25 | Discussion
|
12:25 - 12:30 | Final comments
|
Session 2B: Clinical science abstract session
11:00 - 11:06 | Precision medicine in advanced NENs: Molecular profiling and target actionability real world data
|
Giovanni Farinea, ITA |
11:06 - 11:09 | Discussion
|
11:09 - 11:15 | Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): An international case series
|
Hussein Almeamar, IRL |
11:15 - 11:18 | Discussion
|
11:18 - 11:24 | Nordic NEC 2: Characteristics and treatment outcome in a prospective cohort of 698 patients with high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)
|
Halfdan Sorbye, NOR |
11:24 - 11:27 | Discussion
|
11:27 - 11:33 | A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors
|
Arvind Dasari, USA |
11:33 - 11:36 | Discussion
|
11:36 - 11:42 | Portal vein resection in pancreatic neuroendocrine neoplasms
|
Anna Nießen, GER |
11:42 - 11:45 | Discussion
|
11:45 - 11:51 | Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) – A survival analysis from a prospective observational study
|
Valentina Andreasi, ITA |
11:51 - 11:54 | Discussion
|
11:54 - 12:00 | The global leadership into malnutrition criteria reveals a high percentage of malnutrition which negatively influences overall survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogues
|
Dominique Clement, GBR |
12:00 - 12:03 | Discussion
|
12:03 - 12:09 | Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)
|
Javier Molina Cerrillo, ESP |
12:09 - 12:12 | Discussion
|
LUNCH BREAK
Satellite Symposium – Industry-sponsored
Session 3A: Joint ENETS/ESMO session
Understanding biology to improve patient care...
14:00 - 14:15 | ...in NETs
|
Chrissie Thirlwell, GBR |
14:15 - 14:20 | Discussion
|
14:20 - 14:35 | ...in NECs
|
Julien Hadoux, FRA |
14:35 - 14:40 | Discussion
|
14:40 - 14:55 | ESMO / ENETS GEP NEN guidelines/guidance: Clinical application
|
Angela Lamarca, ESP |
14:55 - 15:00 | Discussion
|
15:00 - 15:07 | Oral Abstract Presentation: Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors
|
Louis de Mestier, FRA |
15:07 - 15:10 | Discussion
|
Session 3B: Basic and translational science abstract session
14:00 - 14:07 | Integrative molecular analysis of lung neuroendocrine neoplasms with different Ki-67 indices identifies a molecular transition group between low- and high-grade neoplasms
|
Michele Simbolo, ITA |
14:07 - 14:10 | Discussion
|
14:10 - 14:17 | Metabolite biomarker discovery for pancreatic neuroendocrine tumors using metabolomic approach
|
Arnaud Jannin, FRA |
14:17 - 14:20 | Discussion
|
14:20 - 14:27 | DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide
|
Elena Trevisani, ITA |
14:27 - 14:30 | Discussion
|
14:30 - 14:37 | Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs): Pathogenesis and therapeutic targets
|
Maria Ines Castanho Martins, GBR |
14:37 - 14:40 | Discussion
|
14:40 - 14:47 | Characterising the tumor microenvironment of multifocal small intestinal NETs
|
Netta Mäkinen, USA |
14:47 - 14:50 | Discussion
|
14:50 - 14:57 | Specific spliceosomic landscapes reveal a possible link between RNA processing and panNETs behaviour
|
Sergio Pedraza-Arévalo, ESP |
14:57 - 15:00 | Discussion
|
Life Achievement Award
15:10 - 15:20 | Laudatio
|
Ulrich-Frank Pape, GER |
15:20 - 15:30 | Recipient and keynote address
|
Bertram Wiedenmann, GER |
COFFEE BREAK
Session 4A: Push the former limits – Rising endoscopic and surgical techniques for the treatment of GEP-NETs
16:00 - 16:10 | Endoscopic treatment of gastroduodenal NETs – Techniques and limits
|
Pradeep Bhandari, GBR |
16:10 - 16:15 | Discussion
|
16:15 - 16:25 | Endoscopic ablation of small pNEN – Techniques and limits
|
Stefano Francesco Crinò, ITA |
16:25 - 16:30 | Discussion
|
16:30 - 16:40 | Resection of advanced neuroendocrine liver metastases – New options and limits
|
Andreas Pascher, GER |
16:40 - 16:45 | Discussion
|
16:45 - 16:55 | Vascular resections for locally advanced pNETs – Techniques and limits
|
Massimo Falconi, ITA |
16:55 - 17:00 | Discussion
|
17:00 - 17:10 | Resection of locally advanced SI-NET – Techniques and limits
|
Peter Stalberg, SWE |
17:10 - 17:15 | Discussion
|
17:15 - 17:22 | Oral Abstract Presentation: Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small-intestinal neuroendocrine tumors - A Phase II surgical trial
|
Maria Danieli, ITA |
17:22 - 17:25 | Discussion
|
17:25 - 17:30 | Closing comments
|
Session 4B: Nurse and dietitian symposium
16:00 - 16:05 | Welcome
|
Wendy Martin, GBR |
New – Transplantation (16:05 - 16:35) |
Moderators: Lise Munk Plum, Deborah Pitfield |
16:05 - 16:15 | Where are we now with liver transplantation and is it an option for NEN patients
|
Stacey Smith, GBR |
16:15 - 16:25 | Transplant Case study
|
Elizabeth Quaglia, GBR |
16:25 - 16:35 | Liver transplantation: Utilising patient involvement to reduce unmet informational needs
|
Nicola Jervis, GBR |
Improved (16:35 - 16:55) |
Moderators: Yasmin Chotai de Lima, Wanda Geilvoet |
16:35 - 16:55 | Nutritional management of insulinomas
|
Tak-Wai Ho, GBR |
Ongoing care – Abstract Session (16:55 - 17:25) |
Moderators: Mette Borre, Wendy Martin |
16:55 - 17:05 | Patient initiated follow up for surgically resected neuroendocrine cancer patients using a digital system – My Record (2023)
|
Emma Ramsey, GBR |
17:05 - 17:15 | Evaluation of the utility of group therapy as a mechanism of delivering facilitated psychosocial support to those with a neuroendocrine neoplasm diagnosis
|
Rebecca Hargreaves, GBR |
17:15 - 17:25 | Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors
|
Margot Tesselaar, NED |
17:25 - 17:30 | Closing comments
|
Wendy Martin, GBR |
Roundtable Discussion: Barriers to access high-quality care in NENs
17:45 - 18:00 | EU NEN Policy Recommendations (Take-home messages)
|
Philippe Ruszniewski, FRA |
18:00 - 18:45 | Roundtable discussion – Physicians', patients' & politicians' perspectives
|
Martyn Caplin, GBR / Massimo Falconi, ITA / Rocio Garcia-Carbonero, ESP / Anna Koumarianou, GRE / Nichola Larkins, BEL / Mark McDonnell, IRL / Marianne Pavel, GER / Catalina Poiana, ROU / Eva Tiensuu Janson, SWE |
- Physicians’ perspective from different geographic regions
- Patients’ perspective (INCA representative)
- Politicians’ perspective (EU Commissioner representative)
Friday, 15 March 2024
Session 5A: Targeted radionuclide therapy – Recent advances
09:00 - 09:15 | PRRT with 177Lu labelled somatostatin analogues: Current status and future directions
|
Christophe Deroose, BEL |
09:15 - 09:30 | Targeted alpha radionuclide therapies – A game changer?
|
Andreas Kjaer, DEN |
09:30 - 09:45 | What is next – New isotopes and novel targets?
|
Tessa Brabander, NED |
09:45 - 09:52 | Oral Abstract Presentation: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study
|
Wouter W. de Herder, NED |
09:52 - 10:10 | Panel Discussion
|
10:10 - 10:17 | Oral Abstract Presentation: Metabolic tumor volume (MTV) as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): A multicentre study
|
David Chan, AUS |
10:17 - 10:20 | Discussion
|
10:20 - 10:27 | Oral Abstract Presentation: PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management
|
Hannes Leupe, BEL |
10:27 - 10:30 | Discussion
|
Session 5B: INCA/ENETS Symposium – Motivating/empowering non-NEN healthcare professionals to think NENs
09:00 - 09:05 | Opening
|
Stephanie Alband, USA / Eva Tiensuu Janson, SWE |
09:05 - 09:20 | Think NENs – Educating primary care physicians about NENs
|
Dermot O'Toole, IRL |
09:30 - 09:35 | Think NENs video collage and a demo of the e-learning platform
|
09:35 - 09:42 | Promoting Think NENs locally and globally
|
Teodora Kolarova, BUL |
09:42 - 09:50 | Key to success and lessons learned
|
Meredith Cummins, AUS |
09:50 - 10:05 | Engaging second-line non-NEN healthcare professionals
|
Martyn Caplin, GBR |
10:05 - 10:10 | Working as a global community to promote better understanding of NENs
|
Mark McDonnell, IRL |
10:10 - 10:27 | Discussion
|
10:27 - 10:30 | Wrap-up and closing comments
|
Stephanie Alband, USA / Eva Tiensuu Janson, SWE |
COFFEE BREAK
A Message from the new ENETS Chair
Session 6: Best NET publications – What's new in the field?
11:10 - 11:35 | Basic science
|
Justo P. Castaño, ESP |
11:35 - 12:00 | Translational science
|
Atsuko Kasajima, GER |
12:00 - 12:25 | Clinical science
|
John Ramage, GBR |